|
CME Information Page
November 4, 2008–eJournal Club Session
Release Date: November 4, 2008
Expiration Date: November 4, 2009
Term of Offering
This activity has a release date of November 4, 2008, and is valid until November 4, 2009. Requests for credit must be received no later than November 4, 2009. This CME activity was planned and produced in accordance with ACCME Essential Areas and Policies. Please refer to the posttest at the end of this activity for further instruction regarding credit.
On completion of the program, please electronically submit the posttest and evaluation for processing. A score of at least 70% is required for credit to be awarded. A certificate of credit will be returned to you within 4–6 weeks. The forms must reach DIME by November 4, 2009. If you have any questions, email DIMEinfo@DIMedEd.org.
Article Title: Incomplete Inhibition of Thromboxane Biosynthesis by Acetylsalicylic Acid: Determinants and Effect on Cardiovascular Risk
Activity Purpose
To identify the mechanisms of thromboxane generation, including the elevated urinary 11-dehydro thromboxane B2 concentration as a valid determinant of cardiovascular risk, and to implement therapies that may reduce this risk
Statement of Need/Program Overview
This program intends to broaden the reach of atherothrombosis prevention and treatment protocols by providing a review of the current literature by today’s foremost experts.
Learning Objectives
On completion of this activity, participants should be able to:
- Describe the mechanisms of thromboxane generation in the context of antiplatelet treatment with aspirin
- Explain the association between elevated urinary 11-dehydro thromboxane B2 concentrations and cardiovascular risk
- Identify modifiable determinants of 11-dehydro thromboxane B2 elevations and select therapies that may subsequently elicit reductions to improve the cardiovascular risk profile
Target Audience
This activity is targeted to physicians with an interest in atherothrombosis.
Sponsored by the Discovery Institute of Medical Education
www.DIMedEd.org
Funding Statement
This activity is funded through an educational grant from the Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership.
Faculty/Editorial Board
Editor-in-Chief:
Christopher P. Cannon, MD
Associate Professor of Medicine
Harvard Medical School
Senior Investigator, TIMI Study Group
Cardiovascular Division
Brigham and Women’s Hospital
Boston, Massachusetts
Discussant
John Eikelboom, MBBS, MSc, FRACP, FRCPA, FRCPC
Associate Professor
Department of Medicine
McMaster University
Hematologist, Thrombosis Service
Hamilton General Hospital
Hamilton, Ontario, Canada
Accreditation Statement
DIME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation Statement
DIME designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Disclosures
DIME requires that all persons who were in a position to control or influence the content of this CME activity disclose all relevant financial relationships with any commercial interest. This information is used to: (1) determine whether a conflict exists, (2) resolve the conflict by initiating a content validation process, and (3) advise learners of this information.
Christopher P. Cannon, MD
Sources of Funding for Research: Accumetrics; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership; GlaxoSmithKline; Merck & Co., Inc.; Merck/Schering-Plough Pharmaceuticals Partnership; Schering-Plough Corporation
Consulting Agreements: None
Speakers’ Bureau/Honorarium Agreements: None
Financial Interests/Stock Ownership: None
Discussion of Off-label, Investigational, or Experimental Drug Use: None
John Eikelboom, MBBS, MSc, FRACP, FRCPA, FRCPC
Sources of Funding for Research: Bayer AG; Bristol-Myers Squibb Company; sanofi-aventis Group
Consulting Agreements: Bristol-Myers Squibb Company; sanofi-aventis Group
Speakers’ Bureau/Honorarium Agreements: Bristol-Myers Squibb Company; sanofi-aventis Group
Financial Interests/Stock Ownership: None
Discussion of Off-label, Investigational, or Experimental Drug Use: None
Inquiries
All inquiries should be directed to:
DIME
222 Merchandise Mart Plaza, Ste 4-160
Chicago, IL 60654
DIMEinfo@DIMedEd.org
©2008 DIME
| 
